Myasthenia Gravis Disease Market Shows Strong Growth with Leading Players
The European region is the second largest market for the
global myasthenia gravis disease owing to the adoption of new therapies,
skilled medical professionals, and availability of advanced treatment
facilities. According to the National Institute of Neurological Disorders and
Stroke (NINDS), an estimated 15 cases of myasthenia gravis occurs per 100,000
people in the United Kingdom every year.
The Americas dominates the global myasthenia
gravis disease market owing to the growing prevalence of muscular
dystrophies such as congenital muscular dystrophies, distal muscular dystrophy,
Becker muscular dystrophies, and others along with the extensive demand for
diagnostic and treatment services. Moreover, major companies are launching FDA
approved drugs thus increasing the commercial access to these drugs worldwide.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5843
The Asia Pacific market is the fastest growing therapeutic
market owing to the large aging population in countries such as Japan and China
coupled with the rising awareness about the long-term effects of muscular
dystrophies. Moreover, the cumulative initiatives of the World Health
Organization (WHO) in countries such as Japan, China, and India are likely to
foster the strengthening of major Asian countries in the future. The Middle
East and Africa is likely to exhibit steady growth in this market due to the
demand for drugs in remote areas and increasing prevalence of neurological
diseases.
Key Players
Some of the key players in the global myasthenia gravis
disease market are Valeant Pharmaceuticals International (U.S.), Sun
Pharmaceuticals Industries Ltd. (India), Piramal Healthcare (India), Novartis
Pharmaceuticals Corporation (Switzerland), Apotex Corporation (Canada), Teva
Pharmaceutical Industries Ltd. (Israel), RPG Life Sciences (India), Cipla (India),
F. Hoffmann Roche La Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.),
Biogen Inc. (U.S.), and AbbVie Inc. (U.S.), GlaxoSmithKline plc (UK), Fresenius
Kabi (Germany), and others.
Segmentation
The global myasthenia gravis disease market has been
segmented on the basis of diagnosis, treatment, and end-user.
·
On the basis of diagnosis, the global myasthenia
gravis disease market can be segmented into imaging, blood tests,
electrodiagnostic, edrophonium test, pulmonary function test, and others. The
imaging segment is classified into X-ray, Computed Tomography (CT), Magnetic
Resonance Imaging (MRI), and others.
·
On the basis of treatment, the global myasthenia
gravis disease market can be segmented into medication, surgery, autologous
Hematopoietic Stem Cell Transplantation (HSCT), plasmapheresis and intravenous
immunoglobulin, and others.
·
The medication segment is divided into
acetylcholinesterase inhibitors, immunosuppressant drugs, steroids, and others.
The acetylcholinesterase inhibitors are classified into atropine, neostigmine,
pyridostigmine, and others. The immunosuppressant drugs are further divided
into prednisone, azathioprine, mycophenolate mofetil, tacrolimus, and
rituximab. The steroids are further divided into prednisone and others. The surgery
is finally divided into thymectomy and others.
·
On the basis of end-user, the global myasthenia
gravis disease market is segmented into hospitals, clinics, academic research
institutes, and others.
Browse Detailed TOC
with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/myasthenia-gravis-disease-market-5843
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Comments
Post a Comment